Significant step forward in ovarian cancer treatment
Almost half of patients who received a targeted drug during treatment for newly diagnosed BRCA-mutated advanced ovarian cancer remain disease free after five years.
Preeti Dudakia, 53, was diagnosed with stage 3 ovarian cancer six years ago. She had a full abdominal hysterectomy, followed by six cycles of chemotherapy. She said: “My mum was diagnosed with ovarian cancer at the age of 60 and because of my family history, the team at The Royal Marsden recommended I try the SOLO-1 trial. I had monthly treatment for two years and now I’m in remission. Since my diagnosis there have been some really rapid advances in treatment for ovarian cancer, and clinical trials like SOLO-1 are a crucial part of this. The trial gave me a sense of purpose and I know the findings will benefit patients for years to come.”
The SOLO-1 trial was funded by AstraZeneca and MSD.
Supported by The Royal Marsden Cancer Charity
Ovarian cancer research at The Royal Marsden is funded by The Royal Marsden Cancer Charity, The Lady Garden Foundation and National Institute for Health Research.